SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) December 13 18, 2018

Cigna Corporation

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation)

1-08323

(Commission File Number)

06-1059331

(IRS Employer

Identification No.)

900 Cottage Grove Road

Bloomfield, Connecticut 06002

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code:

(860) 226-6000

~~Not Applicable~~N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

OnAs ~~December~~previously 13announced, on March 8, 2018, Cigna Corporation ("Cigna" or the ~~State~~"Company") ofentered ~~New~~into ~~York~~an ~~determined~~Agreement ~~that~~and aPlan ~~previously noticed~~of ~~hearing~~Merger in(as ~~that~~amended, ~~State~~the ~~was~~"Merger ~~not~~Agreement") ~~required~~with ~~and~~Express ~~issued~~Scripts ~~its~~Holding ~~approval~~Company, ofa ~~the~~Delaware ~~transaction. Also~~corporation ("Express onScripts"), ~~December~~Halfmoon 13Parent, ~~2018~~Inc., ~~the~~a ~~State~~Delaware ofcorporation ~~California~~and ~~issued~~a ~~its~~direct ~~approval~~wholly ofowned ~~the~~subsidiary ~~transaction. We~~of ~~continue~~Cigna to("Holdco"), ~~work~~Halfmoon ~~with~~I, ~~regulators~~Inc., ina ~~New~~Delaware ~~Jersey,~~corporation ~~the~~and ~~one~~a ~~outstanding~~direct ~~state~~wholly ~~where~~owned ~~approval~~subsidiary isof ~~required~~Holdco, and ~~continue~~Halfmoon toII, ~~expect~~Inc., a ~~that~~Delaware ~~the~~corporation ~~transaction~~and ~~will~~a ~~close~~direct bywholly ~~the~~owned ~~end~~subsidiary of ~~2018~~Holdco, pursuant to which, subject to the ~~satisfaction~~conditions of ~~all~~the ~~closing~~Merger ~~conditions~~Agreement, Holdco will acquire Express Scripts in a cash and stock transaction.

~~This~~On ~~information~~December ~~shall~~18, ~~not~~2018, beCigna ~~deemed~~and ~~"filed"~~Express ~~for~~Scripts ~~purposes~~received ofregulatory ~~Section~~approval 18from of the ~~Securities~~State ~~Exchange Act~~ of ~~1934,~~New asJersey ~~amended~~for (the ~~"Exchange~~transaction. All ~~Act"), or~~required ~~incorporated~~regulatory byapprovals ~~reference~~now inhave ~~any~~been ~~filing~~received ~~under~~and the ~~Securities~~parties ~~Act~~expect ofto ~~1933,~~close ~~as amended, or~~ the transaction ~~Exchange~~on ~~Act~~December ~~whether~~20, ~~made~~2018, ~~before~~subject orto ~~after~~ the ~~date~~satisfaction of ~~this~~all ~~report,~~other ~~except~~closing ~~as shall be expressly set forth by specific reference in such a filing~~conditions.

This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act whether made before or after the date of this report, except as shall be expressly set forth by specific reference in such a filing.

-2-

FORWARD LOOKING STATEMENTS

Information included in this communication, and information which may be contained in other filings with the Securities and Exchange Commission (the “SEC”) and other public statements, contains or may contain forward-looking statements. These forward-looking statements include, among other things, statements of plans, objectives, expectations or intentions, including statements concerning the ability to consummate the proposed merger, on the anticipated timeline or at all, and other statements regarding the parties’' future beliefs, expectations, plans or intentions. You may identify forward-looking statements by the use of words such as “believe,” “expect,” “plan,” “intend,” “anticipate,” “estimate,” “predict,” “potential,” “may,” “should,” “will” or other words or expressions of similar meaning, although not all forward-looking statements contain such terms. Forward-looking statements, including as they relate to Cigna or Express Scripts, the proposed transaction, or the timing of closing, involve risks and uncertainties, both known and unknown. Actual results may differ significantly from those projected or suggested in any forward-looking statements. Cigna and Express Scripts do not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances occurring after the date hereof or to reflect the occurrence of unanticipated events. Any number of factors could cause actual results to differ materially from those contemplated by any forward-looking statements, including, but not limited to, the risks associated with the following: ~~the~~any ~~ability~~change toin ~~obtain~~ the ~~required~~anticipated ~~approvals~~timing toof ~~satisfy~~ the ~~conditions to~~ closing of the ~~combination~~merger, on the ~~anticipated timeline or at all; the~~ possibility that the anticipated benefits from the merger (including anticipated synergies) cannot be realized in full, or at all or may take longer to realize than expected; problems regarding the successful integration of the businesses of Cigna and Express Scripts; unexpected costs regarding the proposed merger; diversion of management’'s attention from ongoing business operations and opportunities; potential litigation associated with the proposed merger; the ability to retain key personnel; the availability of financing; effects on the businesses as a result of uncertainty surrounding the proposed merger; the ability of the combined company to achieve financial, strategic and operational plans and initiatives; the ability of the combined company to predict and manage medical costs and price effectively and develop and maintain good relationships with physicians, hospitals and other health care providers; the impact of modifications to the combined company’'s operations and processes; the ability of the combined company to identify potential strategic acquisitions or transactions and realize the expected benefits of such transactions; the substantial level of government regulation over the combined company’'s business and the potential effects of new laws or regulations or changes in existing laws or regulations; the outcome of litigation relating to the businesses of Cigna and Express Scripts, regulatory audits, investigations, actions and/or guaranty fund assessments; uncertainties surrounding participation in government-sponsored programs such as Medicare; the effectiveness and security of the combined company’'s information technology and other business systems; unfavorable industry, economic or political conditions, including foreign currency movements; acts of war, terrorism, natural disasters or pandemics; and the industry may be subject to future risks that are described in SEC reports filed by Cigna and Express Scripts.

You should carefully consider these and other relevant factors, including those risk factors in this communication and other risks and uncertainties that affect the businesses of Cigna and Express Scripts described in their respective filings with the SEC, when reviewing any forward-looking statement. These factors are noted for investors as permitted under the Private Securities Litigation Reform Act of 1995. Investors should understand it is impossible to predict or identify all such factors or risks. As such, you should not consider the foregoing list, or the risks identified in SEC filings, to be a complete discussion of all potential risks or uncertainties, and should not place undue reliance on forward-looking statements.

-3-

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, ~~the~~each registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Cigna Corporation
Date: December 13, 2018	By:	/s/ Nicole S. Jones
Date: December 19, 2018	By:	/s/ Nicole S. Jones
		Nicole S. Jones
		Executive Vice President and
		Executive Vice President and General Counsel
		General Counsel

-4-

Filing Compare · Cigna Holding Co